

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


# **Single Technology Appraisal**

# Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351

## **Final Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
Company	General
Sanofi (tolebrutinib)	All Wales Therapeutics and Toxicology
Carron (toropratimo)	Centre
Patient/carer groups	Allied Health Professionals Federation
Brain and Spine Foundation	Board of Community Health Councils in
Brain Charity	Wales
MS-UK	British National Formulary
Multiple Sclerosis National Therapy	Care Quality Commission
Centres	Department of Health, Social Services
Multiple Sclerosis Society	and Public Safety for Northern Ireland
Multiple Sclerosis Trust	Healthcare Improvement Scotland
Neuro Therapy Network	Health Technology Wales
Neurological Alliance	Medicines and Healthcare products
Shift.ms	Regulatory Agency
South Asian Health Foundation	Multiple Sclerosis Society Wales
Specialised Healthcare Alliance	National Association of Primary Care
·	National Pharmacy Association
Healthcare professional groups	Neurological Alliance of Scotland
<ul> <li>Association of British Neurologists</li> </ul>	NHS Confederation
British Association of Neuroscience	NHS Wales Joint Commissioning
Nurses	Committee
British Geriatrics Society	Scottish Medicines Consortium
British Neuropathological Society	Wales Neurological Alliance
British Society for Blood and Marrow	Welsh Government
Transplantation	
British Society of Neuroradiologists	Possible comparator companies
British Society of Rehabilitation	Novartis (siponimod)
Medicine	
Chartered Society of Physiotherapy	Relevant research groups
Institute of Neurology	Brain Research UK      British Navyalavijas Basasask Timat
London MS-AHSCT Collaborative	British Neurological Research Trust     Cachage Multiple Salarasia and Bare
Group	Cochrane Multiple Sclerosis and Rare     Discusses of the Control Norways
National Neurosciences Advisory     Croup	Diseases of the Central Nervous
Group	System Group  Genomics England
<ul> <li>Primary Care and Community Neurology Society</li> </ul>	<ul><li>Genomics England</li><li>MRC Clinical Trials Unit</li></ul>
ineurology Society	• IVIING CIII IIGAI THAIS UTIIL

Final stakeholder list for the evaluation of tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351



Consultees	Commentators (no right to submit or appeal)
<ul> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Occupational Therapists</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Therapists in MS</li> <li>Transform MS for All</li> <li>UK Clinical Pharmacy Association</li> <li>UK Multiple Sclerosis Specialist Nurse Association</li> </ul> Others <ul> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Final stakeholder list for the evaluation of tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351

Issue date: August 2025



### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.